$45.44
-1.1%Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
Chief Financial Officer & Chief Operating Officer
Compensation
$970,884
Director of Communications
Director of Investor Relations
Executive Vice President of Marketing & Sales
Compensation
$861,557
Senior Vice President of Operations
Compensation
$531,270
Senior Vice President of Quality & Regulatory Affairs
Senior Vice President, General Counsel & Corporate Secretary
Compensation
$860,439
During the last 12 months, insiders have sold $424K worth of PBH shares, with no buying activity reported.
0
0.00
2.2K
120.44K
-120K
-$120K
0
0.00
1.0K
65.93K
-66K
-$66K
0
0.00
4.0K
238.05K
-238K
-$238K
0
0.00
0
0.00
+0
+$0
No buying activity
Zerillo Jeffrey
Officer: Senior Vp Operations
$246K
Byom John E
Director
$178K
Strong bearish signal with $424K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Heavy recent selling activity. Recent insider sales notably exceed purchasesโmay warrant investigation into company developments.
2 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Persistent selling pressure: Consistent insider selling with weak buy/sell ratio suggests insiders may be capitalizing on current valuation. Exercise caution and review recent earnings quality and management commentary.
PBH - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | June 27, 2025 | August 05, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | July 05, 2024 | August 06, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | June 29, 2023 | August 01, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | June 28, 2022 | August 02, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | June 29, 2021 | August 03, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | June 29, 2020 | August 04, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | June 28, 2019 | July 30, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | June 29, 2018 | July 31, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | June 30, 2017 | August 01, 2017 | 2017 | |
DEF 14A DEF 14A 2016 N/A | June 30, 2016 | August 02, 2016 | 2016 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.